CZ280474B6 - Prostředek pro léčení Alzheimerovy nemoci a způsob jeho přípravy - Google Patents

Prostředek pro léčení Alzheimerovy nemoci a způsob jeho přípravy Download PDF

Info

Publication number
CZ280474B6
CZ280474B6 CS912165A CS216591A CZ280474B6 CZ 280474 B6 CZ280474 B6 CZ 280474B6 CS 912165 A CS912165 A CS 912165A CS 216591 A CS216591 A CS 216591A CZ 280474 B6 CZ280474 B6 CZ 280474B6
Authority
CZ
Czechia
Prior art keywords
disease
alzheimer
aminopyridine
dementia
physostigmine
Prior art date
Application number
CS912165A
Other languages
Czech (cs)
English (en)
Inventor
Szilveszter E. Dr. Vizi
Jenö Dr. Ing. Szilbereky
Nagy Péter Dr. Ing. Literáti
Original Assignee
Biorex Kutató-Fejlesztö Kft.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutató-Fejlesztö Kft. filed Critical Biorex Kutató-Fejlesztö Kft.
Publication of CS216591A3 publication Critical patent/CS216591A3/cs
Publication of CZ280474B6 publication Critical patent/CZ280474B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CS912165A 1990-07-12 1991-07-12 Prostředek pro léčení Alzheimerovy nemoci a způsob jeho přípravy CZ280474B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU904191A HU207444B (en) 1990-07-12 1990-07-12 Method for producing therapeutical preparation suitable for treating alzheimer-disease

Publications (2)

Publication Number Publication Date
CS216591A3 CS216591A3 (en) 1992-04-15
CZ280474B6 true CZ280474B6 (cs) 1996-01-17

Family

ID=10967276

Family Applications (1)

Application Number Title Priority Date Filing Date
CS912165A CZ280474B6 (cs) 1990-07-12 1991-07-12 Prostředek pro léčení Alzheimerovy nemoci a způsob jeho přípravy

Country Status (8)

Country Link
EP (1) EP0607125A1 (de)
JP (1) JPH05508843A (de)
AU (1) AU645826B2 (de)
CZ (1) CZ280474B6 (de)
HU (1) HU207444B (de)
IE (1) IE912431A1 (de)
WO (1) WO1992000737A1 (de)
ZA (1) ZA915462B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE189391T1 (de) * 1993-11-26 2000-02-15 Karla Lehmann Verwendung von lithiumverbindungen zur behandlung und prophylaxe des morbus alzheimer
CA2323177A1 (en) 1998-03-11 1999-09-16 Susan Marie Milosovich Composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278679A (en) * 1980-05-01 1981-07-14 Chromalloy American Corporation Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment

Also Published As

Publication number Publication date
WO1992000737A1 (en) 1992-01-23
AU645826B2 (en) 1994-01-27
CS216591A3 (en) 1992-04-15
HU904191D0 (en) 1990-12-28
EP0607125A1 (de) 1994-07-27
ZA915462B (en) 1992-04-29
JPH05508843A (ja) 1993-12-09
AU8205391A (en) 1992-02-04
HU207444B (en) 1993-04-28
IE912431A1 (en) 1992-01-15
HUT58519A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
Corkin Acetylcholine, aging and Alzheimer's disease: Implications for treatment
Prendergast et al. Central nicotinic receptor agonists ABT-418, ABT-089, and (–)-nicotine reduce distractibility in adult monkeys
DE69233648T2 (de) Verwendung von Galanthaminen zur Linderung von Benzodiazepin-Nebenwirkungen
Maurer et al. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type
Etienne et al. Alzheimer disease: lack of effect of lecithin treatment for 3 months
Thal et al. Oral physostigmine and lecithin improve memory in Alzheimer disease
White et al. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease
EP0584185B1 (de) Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
Snyder Catecholamines in the brain as mediators of amphetamine psychosis
Smith et al. Possible biochemical basis of memory disorder in Alzheimer disease
Bakchine et al. Manic‐like state after bilateral orbitofrontal and right temporoparietal injury: efficacy of clonidine
EP2540297B1 (de) Behandlung von kognitiven Störungen mit (R)-7-Chlor-N-(Quinuclidin-3-yl)Benzo[b]thiophen-2-Carbonsäureamid und dessen pharmazeutisch unbedenklichen Salzen
Brinkman et al. Lecithin and memory training in suspected Alzheimer's disease
Giacobini The second generation of cholinesterase inhibitors: pharmacological aspects
JENSEN et al. Amnesic effects of diazepam:“Drug dependence” explained by state‐dependent learning
Prendergast et al. Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418
Reid The evolution of dementia in idiopathic Parkinson's disease: neuropsychological and clinical evidence in support of subtypes
Emilien et al. Alzheimer disease: neuropsychology and pharmacology
CZ280474B6 (cs) Prostředek pro léčení Alzheimerovy nemoci a způsob jeho přípravy
Mohs et al. Choline chloride effects on memory: correlation with the effects of physostigmine
Perryman et al. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease
Emmerling et al. PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist
Maurer et al. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type
Ravizza¹ et al. Peripheral cholinergic changes and pharmacological aspects in Alzheimer's disease
HU211340A9 (hu) Alzheimer-kór kezelésére alkalmas gyógyászati készítmény és eljárás annak előállítására Az átmeneti oltalom az 1-3. igénypontokra vonatkozik.